These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38055156)

  • 61. Evaluation of the Hemodynamic Effects of Intravenous Amiodarone Formulations During the Maintenance Phase Infusion.
    Lindquist DE; Rowe AS; Heidel E; Fleming T; Yates JR
    Ann Pharmacother; 2015 Dec; 49(12):1317-21. PubMed ID: 26416947
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis.
    Geier D; Geier MR
    Int J Toxicol; 2004; 23(6):369-76. PubMed ID: 15764492
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.
    Thompson WW; Price C; Goodson B; Shay DK; Benson P; Hinrichsen VL; Lewis E; Eriksen E; Ray P; Marcy SM; Dunn J; Jackson LA; Lieu TA; Black S; Stewart G; Weintraub ES; Davis RL; DeStefano F;
    N Engl J Med; 2007 Sep; 357(13):1281-92. PubMed ID: 17898097
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine.
    McMahon AW; Iskander JK; Haber P; Braun MM; Ball R
    Vaccine; 2008 Jan; 26(3):427-9. PubMed ID: 18093701
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of skin tests with polyethylene glycol and polysorbate 80 in the vaccination campaign for COVID-19: results from an Italian multicenter survey.
    Montera MC; Giordano A; Asperti C; Aruanno A; Barzaghi CE; Bignardi D; Borrelli P; Bommarito L; Busa M; Calafiore P; Carusi V; Cinquini M; Cortellini G; Cocchi R; D'Auria F; De Caro F; Demonte A; Di Leo E; Di Lizia M; Di Rienzo A; Fumagalli F; Kihlgren P; Lodi Rizzini F; Macchia D; Manzotti G; Marra AM; Mileto P; Mietta S; Montagni M; Nettis E; Nucera E; Peveri S; Pivetta D; Pirisi M; Ramirez GA; Rivolta F; Rizzi A; Savoia A; Pedicini A; Scarpa A; Zambito M; Zisa G; Yacoub MR
    Eur Ann Allergy Clin Immunol; 2024 Jan; 56(1):17-25. PubMed ID: 36927838
    [No Abstract]   [Full Text] [Related]  

  • 66. Anaphylaxis Due to the Excipient Polysorbate 80.
    Palacios Castaño MI; Venturini Díaz M; Lobera Labairu T; González Mahave I; Del Pozo Gil MD; Blasco Sarramián A
    J Investig Allergol Clin Immunol; 2016; 26(6):394-396. PubMed ID: 27996954
    [No Abstract]   [Full Text] [Related]  

  • 67. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children.
    Nolan T; Richmond PC; McVernon J; Skeljo MV; Hartel GF; Bennet J; Basser RL
    Influenza Other Respir Viruses; 2009 Nov; 3(6):315-25. PubMed ID: 19903213
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Measurement and decomposition kinetics of residual hydrogen peroxide in the presence of commonly used excipients and preservatives.
    Towne V; Oswald CB; Mogg R; Antonello J; Will M; Gimenez J; Washabaugh M; Sitrin R; Zhao Q
    J Pharm Sci; 2009 Nov; 98(11):3987-96. PubMed ID: 19283757
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Osmotic and stimulant laxatives for the management of childhood constipation.
    Gordon M; MacDonald JK; Parker CE; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD009118. PubMed ID: 27531591
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Allergy to mercurothiolate in an infant during heparinization of an intracaval catheter].
    Chastagner P; Morali A; Trechot JP; May I; Vidailhet M
    Presse Med; 1988 Apr; 17(16):795-6. PubMed ID: 2968567
    [TBL] [Abstract][Full Text] [Related]  

  • 71. PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects.
    Cushing DJ; Kowey PR; Cooper WD; Massey BW; Gralinski MR; Lipicky RJ
    Eur J Pharmacol; 2009 Apr; 607(1-3):167-72. PubMed ID: 19232340
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analyzing excipient-related adverse events in antiseizure drug formulations.
    Ionova Y; Peterson T; Wilson L
    Epilepsy Res; 2022 Aug; 184():106947. PubMed ID: 35661571
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
    Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
    J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Toxic additives in medication for preterm infants.
    Whittaker A; Currie AE; Turner MA; Field DJ; Mulla H; Pandya HC
    Arch Dis Child Fetal Neonatal Ed; 2009 Jul; 94(4):F236-40. PubMed ID: 19158148
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Regression of language and non-language skills in pervasive developmental disorders.
    Meilleur AA; Fombonne E
    J Intellect Disabil Res; 2009 Feb; 53(2):115-24. PubMed ID: 19054269
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation.
    Li M; Du Y; Wang Q; Sun C; Ling X; Yu B; Tu J; Xiong Y
    Drug Dev Ind Pharm; 2016; 42(4):676-84. PubMed ID: 26288999
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.
    van der Vossen AC; van der Velde I; Smeets OS; Postma DJ; Eckhardt M; Vermes A; Koch BC; Vulto AG; Hanff LM
    Eur J Pharm Sci; 2017 Mar; 100():205-210. PubMed ID: 28126558
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Application of a statistical method to the absorption of a new model drug from micellar and lipid formulations--evaluation of qualitative excipient effects.
    Kuentz M; Wyttenbach N; Kuhlmann O
    Pharm Dev Technol; 2007; 12(3):275-83. PubMed ID: 17613891
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early exposure to thimerosal-containing vaccines and children's cognitive development. A 9-year prospective birth cohort study in Poland.
    Mrozek-Budzyn D; Majewska R; Kiełtyka A
    Eur J Pediatr; 2015 Mar; 174(3):383-91. PubMed ID: 25185528
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers.
    James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ
    Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.